Tag: BP11
CuraTeQ Biologics’ successful phase 1 trial of BP11
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, announced that their Omalizumab biosimilar candidate BP11 has met the Phase 1 trial endpoints vis-à-vis the EU...
This function has been disabled for HealthTekPak.